Item does not contain fulltextVariable domains of llama heavy-chain antibodies (VHH) are becoming a potent tool for a wide range of biotechnological and medical applications. Because of structural features typical of their single-domain nature, they are relatively easy to produce in lower eukaryotes, but it is not uncommon that some molecules have poor secretion efficiency. We therefore set out to study the production yield of VHH. We computationally identified five key residues that are crucial for folding and secretion, and we validated their importance with systematic site-directed mutations. The observation that all key residues were localised in the V segment, in proximity of the J segment of VHH, led us to study the importance of J se...
Abstract Antibodies are central to the growing sector of protein therapeutics, and increasingly they...
Monoclonal antibodies are a remarkably successful class of therapeutics used to treat a wide range o...
The commercial development of plant-based antibody production platforms is often limited by low and ...
Variable domains of llama heavy-chain antibodies (VHH) are becoming a potent tool for a wide range o...
Variable domains of camelid heavy chain antibodies (VHHs) are the smallest available antigen binding...
Variable domains of camelid heavy chain antibodies (VHHs) are the smallest available antigen binding...
Microbicides offer a promising way to prevent HIV infection in developing countries. Llama heavy cha...
The aim of this study was to improve production level of llama heavy chain antibody fragments (V (HH...
A high production yield and good stability are required for the large scale application of llama hea...
A llama single domain antibody (dAb) library designed and constructed to contain only heavy chain an...
A set of 70 variable domains of heavy chain Camelid antibodies (VHHs) were grown under identical con...
Antibody engineering reveals the important role of J segments in the production efficiency of llam
Camelids have next to their normal antibodies, a unique subset of antibodies lacking light chains. T...
The llama is able to generate a unique class of antibody. The heavy chain immunoglobulins consist on...
Rodent monoclonal antibodies with specificity towards important biological targets are developed for...
Abstract Antibodies are central to the growing sector of protein therapeutics, and increasingly they...
Monoclonal antibodies are a remarkably successful class of therapeutics used to treat a wide range o...
The commercial development of plant-based antibody production platforms is often limited by low and ...
Variable domains of llama heavy-chain antibodies (VHH) are becoming a potent tool for a wide range o...
Variable domains of camelid heavy chain antibodies (VHHs) are the smallest available antigen binding...
Variable domains of camelid heavy chain antibodies (VHHs) are the smallest available antigen binding...
Microbicides offer a promising way to prevent HIV infection in developing countries. Llama heavy cha...
The aim of this study was to improve production level of llama heavy chain antibody fragments (V (HH...
A high production yield and good stability are required for the large scale application of llama hea...
A llama single domain antibody (dAb) library designed and constructed to contain only heavy chain an...
A set of 70 variable domains of heavy chain Camelid antibodies (VHHs) were grown under identical con...
Antibody engineering reveals the important role of J segments in the production efficiency of llam
Camelids have next to their normal antibodies, a unique subset of antibodies lacking light chains. T...
The llama is able to generate a unique class of antibody. The heavy chain immunoglobulins consist on...
Rodent monoclonal antibodies with specificity towards important biological targets are developed for...
Abstract Antibodies are central to the growing sector of protein therapeutics, and increasingly they...
Monoclonal antibodies are a remarkably successful class of therapeutics used to treat a wide range o...
The commercial development of plant-based antibody production platforms is often limited by low and ...